当院糖尿病内科医師 岩本真彦らの論文がPharmacology Research & Perspectivesに掲載されました

論文タイトル：The sodium-glucose co-transporter 2 inhibitor tofogliflozin suppresses atherosclerosis through glucose lowering in ApoE-deficient mice with streptozotocin-induced diabetes.
[Pharmacol Res Perspect. 2022 Aug;10(4):e00971. doi:10.1002/prp2.971]